Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a guideline for the treatment of graft failure after hematopoietic stem cell
transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose
total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial
graft failure.
The graft will consist of bone marrow or G-CSF mobilized peripheral blood from a
haploidentical related donor. The source of stem cells will be determined by the transplant
team based on factors such as patient's age, medical history, donor availability and will be
according to the current University of Minnesota Blood and Marrow Transplantation Program
selection guidelines.